Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to
2020
Published on October 2011

Report Summary

Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, ' Vargatef (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020' provides Vargatef
sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug
sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes
information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalData's
proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and
featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by
GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Vargatef including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Vargatef including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2015-2020 for Vargatef in the US, EU5 and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020 (From Slideshare) Page 1/6


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8
3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12
5 Vargatef 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Vargatef 17
5.4.1 NSCLC Market 17
5.4.2 High Response Rate for Second Line Treatment 17
5.4.3 Unmet Need 17
5.4.4 Oral Dosing 17
5.4.5 Targeted Therapy 17
5.5 Drug Risk Benefit Score 18
5.5.1 Efficacy 18
5.5.2 Safety 18
5.5.3 Compliance 18
5.5.4 Dosing Convenience 18
5.6 Intensity of Competition 19
5.7 Sales forecast 19
5.7.1 Target Patient Pool of Vargatef 19
5.7.2 Dosing 21
5.7.3 Market Penetration 21
5.7.4 Annual Cost of Therapy 21
5.7.5 Sales Projections of Vargatef 22
6 NSCLC Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 32
6.3.1 Coverage 32
6.3.2 Secondary Research 33
6.3.3 Forecasting 33



6.3.4 Number of Patients Approved to take the Drug 33
6.3.5 Net Penetration of Drug 33
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 35
6.3.8 Primary Research 35
6.3.9 Expert Panels 35
6.4 Contact Us 35
6.5 Disclaimer 35
6.6 Sources 36

1.1 List of Tables

Table 1: NSCLC, Incidences and Mortality, 2008-2030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 2009'2020 9
Table 3: Drug Risk Benefit Score 18
Table 4: NSCLC, The US, EU-5 and Japan, Sales Forecast for Vargatef ($m), 2015'2020 22
Table 5: NSCLC, The US, Sales Forecast for Vargatef ($m), 2015'2020 23
Table 6: NSCLC, The UK, Sales Forecast for Vargatef ($m), 2015'2020 24
Table 7: NSCLC, France, Sales Forecast for Vargatef ($m), 2015'2020 25
Table 8: NSCLC, Germany, Sales Forecast for Vargatef ($m), 2015'2020 26
Table 9: NSCLC, Italy, Sales Forecast for Vargatef ($m), 2015'2020 27
Table 10: NSCLC, Spain, Sales Forecast for Vargatef ($m), 2015'2020 28
Table 11: NSCLC, Japan, Sales Forecast for Vargatef ($m), 2015'2020 29

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) '(% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: Percentage Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 2009'2020 9
Figure 7: Oncology, Global, Incidence (in million), 2008-2030 10
Figure 8: NSCLC, Global, Incidence (in million), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Vargatef 19
Figure 14: Vargatef, NSCLC, Global Sales Forecast ($m), 2015'2020 21
Figure 15: Vargatef, NSCLC, The US, Sales Forecast ($m), 2015'2020 23
Figure 16: Vargatef, NSCLC, The UK, Sales Forecast ($m), 2015'2020 24
Figure 17: Vargatef, NSCLC, France, Sales Forecast ($m), 2015'2020 25
Figure 18: Vargatef, NSCLC, Germany, Sales Forecast ($m), 2015'2020 26
Figure 19: Vargatef, NSCLC, Italy, Sales Forecast ($m), 2015'2020 27
Figure 20: Vargatef, NSCLC, Spain, Sales Forecast ($m), 2015'2020 28
Figure 21: Vargatef, NSCLC, Japan, Sales Forecast ($m), 2015'2020 29
Figure 22: Vargatef, NSCLC, Sales Forecast by Country ($m), 2020 30
Figure 23: GlobalData Methodology 32



Figure 24: Drug Model Diagram 34
Figure 25: Patients Approved for the Drug 34


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Andere mochten auch

Andere mochten auch (17)

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Vargatef (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020